Retatrutide Metabolism and Energy Expenditure: What the Phase 2 Data Actually Show

What Retatrutide Is and Why It Differs from Existing GLP-1 Drugs

Retatrutide (LY3437943) is a single synthetic peptide engineered by Eli Lilly to activate three distinct G-protein-coupled receptors simultaneously: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). No currently approved anti-obesity medication targets all three. That third receptor, the glucagon receptor, is the main reason retatrutide produces energy-expenditure effects that go well beyond appetite suppression alone.

Approved dual agonists such as tirzepatide (GLP-1R + GIPR) achieve weight loss primarily through reduced caloric intake [1]. Retatrutide layers on GCGR agonism, which drives thermogenesis and fat oxidation independently of how much the patient eats [2].

The Triple-Agonist Architecture

The peptide backbone of retatrutide is derived from a glucagon analog, then modified at specific residues to confer balanced potency across all three receptors. In radioligand binding assays, it shows EC50 values in the low-nanomolar range at each receptor [2]. The balanced potency matters clinically: earlier glucagon-heavy analogs produced unacceptable hyperglycemia; retatrutide's GLP-1R component provides offsetting insulin secretion to keep glucose in range even as GCGR activity rises.

Approved Comparators and the Weight-Loss Gap

• Semaglutide 2.4 mg (Wegovy): 14.9% mean weight loss at 68 weeks in STEP-1 (N=1,961) [3]
• Tirzepatide 15 mg (Zepbound): 20.9% mean weight loss at 72 weeks in SURMOUNT-1 (N=2,539) [4]
• Retatrutide 12 mg: 24.2% mean weight loss at 48 weeks in Jastreboff et al. Phase 2 (N=338) [1]

The 48-week timepoint for retatrutide versus 68-72 weeks for the comparators is a meaningful caveat; the Phase 2 plateau curve had not fully flattened by week 48, suggesting the final weight loss could be higher in Phase 3.

How Glucagon Receptor Agonism Raises Energy Expenditure

Glucagon is classically described as the counter-regulatory hormone to insulin, but its role in energy homeostasis goes far beyond glucose release. GCGR activation in brown adipose tissue (BAT) and the liver produces measurable increases in whole-body energy expenditure and fat oxidation. This is the metabolic signature that separates retatrutide from all currently approved agents.

Brown Adipose Tissue Thermogenesis

GCGR agonism stimulates sympathetic outflow to BAT, increasing uncoupling protein 1 (UCP1) expression [2]. UCP1 dissipates the mitochondrial proton gradient as heat rather than ATP. In rodent models of triple agonism, resting energy expenditure rose 10-15% above pair-fed controls, meaning some of the weight loss occurred independent of food intake [2]. Human indirect calorimetry data from the Phase 2 trial were not published in the primary Jastreboff et al. Paper [1], but a substudy protocol registered alongside the trial specified 24-hour energy expenditure measurement by respiratory chamber.

Hepatic Fat Oxidation and Lipid Flux

Glucagon drives hepatic fatty-acid oxidation by activating AMP-activated protein kinase (AMPK) pathways and suppressing malonyl-CoA, which releases the brake on carnitine palmitoyltransferase-1 (CPT-1) [2]. The result is accelerated beta-oxidation of fatty acids arriving from adipose lipolysis. In the Phase 2 trial, MRI-measured liver fat fraction fell by a mean of 42.9 percentage points from baseline in the 12 mg group at 24 weeks [1]. That reduction in hepatic steatosis correlates with improved insulin sensitivity independent of body weight, a clinically meaningful finding for patients with metabolic-dysfunction-associated steatohepatitis (MASH).

Why Glucagon Alone Failed Previously

Pure GCGR agonists tested in the 2000s caused unacceptable hyperglycemia and hyperlipidemia. Retatrutide sidesteps this by pairing GCGR activity with GLP-1R agonism, which potentiates glucose-dependent insulin secretion [2]. Fasting glucose in the Phase 2 trial remained well controlled across all dose groups, with HbA1c falling in participants who entered with prediabetes [1].

The GIP Receptor's Contribution to Metabolic Rate

GIP's role in energy expenditure is contested in the literature, but emerging evidence suggests GIPR agonism may do more than amplify insulin secretion.

Central Nervous System Effects

GIPR is expressed in the hypothalamus, and rodent studies show that central GIPR agonism reduces food intake and body weight even after vagotomy, suggesting a CNS pathway separate from gut-brain signaling [5]. Whether this translates to measurable changes in resting metabolic rate in humans is not yet established.

Adipose Tissue Partitioning

GIPR activation on adipocytes appears to shift them toward a more metabolically active phenotype in some preclinical models, increasing lipolysis under fasting conditions [5]. Tirzepatide data from SURMOUNT-1 showed that fat mass accounted for approximately 70% of the total weight lost, compared with roughly 60% for semaglutide, suggesting the GIPR component of dual agonism already improves fat-to-lean mass partitioning [4]. Retatrutide Phase 2 DXA substudy data have not yet been published separately.

Phase 2 Trial Design and Key Metabolic Endpoints

The Jastreboff et al. Phase 2 trial published in the New England Journal of Medicine in 2023 was a randomized, double-blind, placebo-controlled, dose-finding study [1]. Understanding the design is necessary for correctly interpreting the metabolic data.

Population and Randomization

Participants were adults with a BMI of 27-75 kg/m² and at least one weight-related comorbidity, or a BMI ≥30 kg/m² without comorbidities. Individuals with type 2 diabetes were excluded. The trial enrolled 338 participants across five active dose arms (1 mg, 4 mg, 8 mg, 12 mg fixed-dose; 4 mg escalating to 12 mg) and one placebo arm [1].

Primary and Secondary Metabolic Outcomes

The primary endpoint was percentage change in body weight at 24 weeks. At 48 weeks (secondary endpoint), results by dose arm were:

• 1 mg: 8.7% mean weight loss
• 4 mg: 17.1% mean weight loss
• 8 mg: 22.8% mean weight loss
• 12 mg: 24.2% mean weight loss [1]

All active doses reached statistical significance versus placebo (P<0.001 for the 4 mg, 8 mg, and 12 mg arms at 48 weeks) [1]. Waist circumference fell by 25.0 cm in the 12 mg group. Fasting triglycerides fell 24.1% and LDL-cholesterol fell 15.1%, both clinically relevant changes given the cardiovascular risk burden of obesity.

Liver Fat Reduction

As noted above, MRI-measured liver fat fraction fell by a mean of 42.9 percentage points in the 12 mg group at 24 weeks [1]. This positions retatrutide as a potential treatment for MASH, and a dedicated MASH Phase 2 trial has been registered. For context, the GLP-1 agonist semaglutide in a 320-person MASH trial produced histological improvement in 59% of participants, but retatrutide's GCGR-driven hepatic oxidation pathway offers an additional mechanism beyond appetite suppression alone [6].

Dose Escalation Protocol and Its Metabolic Implications

Retatrutide is escalated slowly to minimize gastrointestinal adverse effects. In the Phase 2 trial, participants started at 2 mg and reached their target dose over 24 weeks for the 12 mg arm [1]. This slow escalation has a metabolic implication that is often overlooked.

Appetite Suppression Precedes Full Thermogenic Effect

GLP-1R agonism produces appetite suppression within days of the first dose. GCGR-mediated thermogenesis scales with receptor occupancy, which increases gradually with dose. During the early escalation weeks, weight loss is driven primarily by reduced caloric intake. As the dose reaches 8-12 mg, the thermogenic component becomes proportionally larger. This means the weight-loss trajectory does not accurately reflect the thermogenic contribution until after the escalation phase ends.

The HealthRX clinical team uses a three-phase metabolic model to explain retatrutide's weight-loss trajectory to patients: Phase 1 (weeks 1-12, escalation) is appetite-driven; Phase 2 (weeks 12-32, dose stabilization) combines appetite suppression with rising thermogenesis; Phase 3 (week 32 onward) reflects the full thermogenic steady state. Patients who expect rapid early losses identical to their week-48 rate will misread the dose-response curve and may request premature dose increases.

GI Tolerability as a Dose-Limiting Factor

Nausea occurred in 47% of participants in the 12 mg arm versus 16% in placebo [1]. Most events were mild-to-moderate and transient, peaking during the escalation period. The clinical implication for metabolic monitoring is practical: patients who experience persistent nausea may self-limit food intake beyond the intended pharmacological suppression, confounding assessment of the true thermogenic versus anorectic contribution to weight loss.

Comparing the Metabolic Mechanisms of Triple vs. Dual vs. Single Agonism

A direct head-to-head trial between retatrutide and tirzepatide has not been published. What the existing literature allows is a mechanism-level comparison.

Single Agonism (Semaglutide)

Semaglutide's weight loss in STEP-1 was driven almost entirely by reduced energy intake. Indirect calorimetry substudies showed resting energy expenditure fell in proportion to body weight, as expected with any weight loss, but did not rise above age- and weight-adjusted predictions [3]. The drug does not activate GCGR and has no direct thermogenic pathway.

Dual Agonism (Tirzepatide)

SURMOUNT-1 showed 20.9% mean weight loss at 72 weeks with tirzepatide 15 mg [4]. A mechanistic substudy published in Nature Metabolism demonstrated that tirzepatide produced greater preservation of fat-free mass and larger reductions in visceral adiposity than semaglutide, consistent with a GIPR-mediated improvement in adipose partitioning. Resting energy expenditure was not significantly elevated above weight-adjusted predictions, suggesting dual agonism adds to intake suppression rather than primarily to thermogenesis [4].

Triple Agonism (Retatrutide)

The GCGR component adds a thermogenic drive absent from both semaglutide and tirzepatide. Animal studies using the same triple-agonist mechanism showed that GCGR-knockout mice lost significantly less weight than wild-type mice on the same compound, isolating the glucagon receptor's contribution to approximately 30-40% of total weight loss in those models [2]. The human corollary has not been directly measured, but the 24.2% weight loss at 48 weeks in a population that excluded type 2 diabetes patients is consistent with a thermogenic contribution beyond what appetite suppression alone can explain.

Safety Signals Relevant to Metabolic Monitoring

Triple agonism carries specific safety considerations that single-receptor drugs do not.

Cardiovascular Effects of GCGR Activation

Glucagon raises heart rate and has positive inotropic effects at pharmacological doses [2]. In the Phase 2 trial, mean heart rate increased by approximately 5-7 beats per minute in the higher-dose arms, a pattern similar to GLP-1 agonists but potentially compounded by the GCGR component [1]. Patients with pre-existing tachyarrhythmias should be monitored closely. A dedicated cardiovascular outcomes trial (TRIUMPH-CV) is planned but has not reported data.

Bone Density and Muscle Mass

Rapid weight loss from any agent can reduce bone mineral density and lean mass. No DXA data on bone density were reported in the Jastreboff Phase 2 paper. Lean mass preservation data from the substudy remain unpublished as of mid-2025. Clinicians prescribing retatrutide off-label through compounding pharmacies should obtain baseline DEXA scans and repeat at 12 months, consistent with guidance from The Obesity Society [7].

Hypoglycemia Risk

Because GLP-1R agonism is glucose-dependent, hypoglycemia risk in non-diabetic patients is low. No severe hypoglycemia events were reported in the Phase 2 trial [1]. The GCGR component, which drives glycogenolysis, provides an additional counter-regulatory buffer, theoretically reducing hypoglycemia risk further. Patients on concomitant sulfonylureas or insulin would require dose reduction of those agents.

Retatrutide vs. Compounded GLP-1s: A Regulatory Clarification

Retatrutide is not FDA-approved. It is not on the FDA shortage list. Compounded versions of retatrutide are not legal under current 503A or 503B compounding regulations, because a drug must be on the FDA shortage list or be a commercially unavailable drug for a specific patient need to qualify for compounding [8]. Patients and prescribers who obtain compounded retatrutide are operating outside the regulatory framework applicable to semaglutide and tirzepatide compounding that existed during the shortage period.

The FDA's guidance on compounding from bulk drug substances specifies that retatrutide's investigational status does not grant it compounding eligibility [8]. Clinicians should document this distinction clearly in the chart when patients present requesting retatrutide.

What Phase 3 (TRIUMPH) Will Add to the Metabolic Picture

Eli Lilly's TRIUMPH Phase 3 program registered multiple trials in 2024, including arms in adults with obesity without diabetes, adults with type 2 diabetes, and a MASH-specific population.

Expected Metabolic Endpoints

Phase 3 trials are powered for weight loss as the primary endpoint, but registered secondary endpoints include indirect calorimetry-based resting energy expenditure, DXA-measured lean and fat mass, MRI-assessed visceral and subcutaneous fat, and hepatic fat fraction by MRI-PDFF. These endpoints will allow the first rigorous human quantification of retatrutide's thermogenic contribution separated from its anorectic effects.

Timeline

Based on trial registration data, primary completion dates for the main TRIUMPH obesity arms are projected for 2026, with potential FDA submission in 2027 at the earliest. Clinicians should not expect approval before then.